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TAVR FOR THE TREATMENT OF PURE AORTIC VALVE REGURGITATION
Pure AR is far less frequent than symptomatic aortic stenosis, affecting w13% of patients with isolated, native left-sided valvular heart disease (6) . Due to concerns of insufficient anchoring of conventional transcatheter heart valves within the noncalcified aortic annulus, surgical valve replacement remains the treatment of choice in operable patients. However, the implantation of conventional transcatheter heart valves not specifically designed for the treatment of the regurgitant aortic valves has been described in patients considered at prohibitive risk for open-heart surgery on a compassionate use basis (7, 8) . Due to the self-expanding frame with additional anchoring by means of abutment also against the ascending aorta, the self-expanding MCV has been used in the majority of cases. There is a single report describing the use of the transapical Medtronic Engager bioprosthesis (9) and another with the Edwards SAPIEN XT valve (ESV) in a patient with AR in the presence of a left ventricular assist device (10) .
Adequate deployment of transcatheter heart valves in an annulus with absent or minimal calcification remains challenging due to the absence of fluoroscopic landmarks, the need for oversizing, and the frequently concomitant dilation of the aortic root and/or the ascending aorta. Due to these technical and anatomical issues, valve deployment is less predictable and may be complicated by supra-annular (11) (Figure 1 ) or ventricular dislocation of the prosthesis, the latter possibly occurring up to several hours after implantation (12) . To overcome these technical concerns, some groups advocate the use of 2 pigtail catheters for improved annular delineation (18) . Mid-term results after 6 months of follow-up in 31 patients (19) and after 1 year in 10 patients (20) showed sustained symptomatic improvement and good hemodynamic performance of the bioprosthesis with more than mild AR in only 1 patient (successfully treated with VIV implantation of an ESV after 3 months of follow-up). A similar system, the J-Valve (JC Medical, Inc., Redwood City, California), currently undergoes a first-in-human investigation in China. The recently published 90-day follow-up results showed favorable procedural outcomes with only minor AR in 90% of the patients. In 1 patient, conversion to surgical valve replacement was required due to device embolization into the ascending aorta (21) .
The Helio transcatheter aortic docking device (Edwards Lifesciences) is another system designed to enable annular fixation of a standard balloonexpandable SAPIEN XT transcatheter heart valve in patients with a minimally calcified aortic annulus.
The initial version with a combined transapicaltransfemoral approach (22) has recently evolved into a fully transfemoral system that was successfully implanted in a patient with severe AR in 2013 (23) . 
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TAVR IN BAV
BAV is the most frequent congenital heart defect with a prevalence of 0.5% to 2.0%, mostly affecting males (24, 25) . In as many as 50% of the cases, the valvular anatomic changes coexist with dilation of the aortic root and/or the ascending aorta (26) . Approximately 20% of the patients 80 years of age and older have evidence of bicuspid anatomy (either congenital or due to fusion of severely degenerated leaflets) as observed during surgical aortic valve replacement (27) . In clinical practice, a relatively small proportion of patients (w5%) evaluated for TAVR presents with bicuspid anatomy. TAVR in BAV remains challenging due to following anatomic and procedural factors: Praz et al.
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with impaired hemodynamic outcomes (increased transvalvular gradient or paravalvular leak) ( Figure 3 ). In summary, TAVR may be considered a treatment alternative in selected patients with bicuspid In this 56-year-old candidate for left ventricular assist device implantation as a bridge to heart transplantation, transfemoral delivery of a 27-mm Lotus bioprosthesis (Boston Scientific, Marlborough, Massachusetts) into a degenerated 27-mm stentless Shelhigh valved conduit
Off-Label Use of TAVR Devices anatomy. Incomplete valve deployment, particularly when using self-expandable bioprostheses, may result in asymmetry of the frame favoring the occurrence of an associated paravalvular leak (41) and accelerating valve deterioration (42) . Durability needs to be addressed by collecting long-term data.
TAVR FOR THE TREATMENT OF TRANSCATHETER AORTIC VALVE DEGENERATION
Implantation of a second transcatheter heart valve either "in series" (i.e., 2 functioning valves) or in a TAVR device (i.e., only 1 functioning prosthesis) has been initially described as a bail-out strategy for the treatment of device embolization (43) Praz et al.
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Although several modes of transcatheter heart valve deterioration have been identified, including ( Figure 5 ). In the absence of radiopaque markers, the procedure has to be carefully guided by transesophageal echocardiography (69) . Implantation of the transcatheter heart valve too low in the left ven- Praz et al. Tables 1 and 2 . Praz et al.
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Off-Label Use of TAVR Devices D E C E M B E R 2 1 , 2 0 1 5 : 1 7 7 7 -9 6 therapy (either with aspirin or clopidogrel) was found to be insufficient in preventing late valve thrombosis (66, 76) . (Table 3) .
However, due to the D-shape of the annuloplasty rings, paravalvular leaks were frequently observed and may be associated with significant hemolysis.
From a technical point of view, mitral VIR procedures are more complex than VIV procedures for several reasons. As demonstrated by in vitro testing, the initially elliptical annuloplasty ring has to become circular during device implantation to accommodate the transcatheter heart valve and ensure sufficient sealing. Accordingly, valve deployment can only be performed in selected deformable complete and rigid semilunar annuloplasty devices (Online Table 1 ). In contrast, complete rigid rings are associated with an increased risk of stent deformation, impairing leaflet geometry with the possible appearance of transvalvular regurgitation. Moreover, the ring circularization during deployment also has relevant implications with regard to valve sizing. Rather than the labeled device diameter as specified by manufacturer, ring perimeter and area, which remain constant after circularization, are used for valve 
Praz et al.
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Off-Label Use of TAVR Devices In summary, VIR implantation may be considered as an alternative to reoperation in selected high-risk surgical patients after careful evaluation of feasibility depending on ring construction and size.
However, ring deformability cannot be accurately predicted in every case, so that additional data are needed to identify factors associated with impaired circularization (82) .
MITRAL VALVE-IN-NATIVE RING IMPLANTATION.
As a variant of mitral VIR implantation, deployment of transcatheter heart valves into severely In selected patients presenting with severely calcified mitral valve annulus not amenable to decalcification (A, B arrows delineate the calcified native mitral valve annulus), on pump transatrial implantation of a transcatheter heart valve emerged as a possible alternative. After predilation, a 26-mm Edwards SAPIEN XT valve was implanted via a transatrial approach using the Edwards Ascendra delivery catheter (C, D) in this 61-year-old male patient with severe mitral stenosis (mean gradient, 17 mm Hg; mitral valve area, 0.9 cm 2 ). To avoid migration, the valve was sutured to the mitral annulus (E). Echocardiographic assessment showed mild residual mitral regurgitation. The post-operative course was uneventful.
Off-Label Use of TAVR Devices following years, several case reports and 4 case series confirmed the safety and feasibility of this intervention using either the Melody valve or the ESV (Table 4) . Only 1 case of valve thrombosis involving a Melody valve has been reported so far and was shown to be related to heparin-induced thrombocytopenia (72) .
Several technical issues need to be considered when planning a tricuspid VIV implantation. First, the most appropriate access route needs to be Online Table 2 Additionally, the high costs of the treatment need to be balanced against the net clinical benefit. Considering these points, the technique should be offered to patients presenting with intractable heart failure on a compassionate use basis. PR ¼ pulmonary regurgitation; other abbreviations as in Table 2 .
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performed with the currently available devices are limited by the design of tricupid rings. 
